Query: Preclinical ADME/Toxicology and safety characterization of candidate small molecules that preserve or enhance cochlear hair cell mechanotransduction: inner ear distribution studies, blood–labyrinth barrier permeability, systemic exposure metrics, organ toxicity assessments, and any available human tolerability data

Preclinical ADME and toxicology studies for candidate small molecules intended to preserve or enhance cochlear hair cell mechanotransduction require an integrated evaluation of several interdependent parameters. Inner ear distribution, blood–labyrinth barrier (BLB) permeability, systemic exposure metrics, broader organ toxicity assessments, and initial human tolerability data form the core of such characterization.

Inner ear distribution studies are critical because the drug must successfully reach the cochlear hair cells embedded within the temporal bone. Preclinical assessments combine functional auditory tests—such as Auditory Brainstem Response (ABR) and Distortion Product Otoacoustic Emissions (DPOAE)—with histological evaluations (cytocochleograms) to ascertain not only the presence of the drug in cochlear compartments but also its effects on hair cell integrity (pasdelou2024ototoxicityahigh pages 10-11, pasdelou2024ototoxicityahigh pages 2-3). Moreover, pharmacokinetic analyses often involve sampling perilymph from animal models, which underscores how cochlear drug concentrations can differ markedly from plasma levels due to local tissue retention.

The BLB is a specialized barrier analogous to the blood–brain barrier. Its permeability is a determining factor for the inner ear distribution of small molecules. Preclinical models have demonstrated that systemic inflammatory challenges (e.g., lipopolysaccharide administration) can compromise the BLB and enhance cochlear penetration of compounds. However, while qualitative changes are evident, precise quantitative analyses of BLB permeability remain limited in the literature (pasdelou2024ototoxicityahigh pages 16-16).

Systemic exposure metrics, another critical aspect, help delineate whether a candidate compound exhibits preferential retention in the inner ear or disseminates systemically. For instance, studies with compounds like cisplatin reveal prolonged cochlear retention in spite of rapid systemic clearance, highlighting a potential risk of localized toxicity even when plasma levels decline (pasdelou2024ototoxicityahigh pages 16-16, sawamura2021analysisofpharmacokinetics pages 2-4). These metrics are determined through comprehensive pharmacokinetic studies, integrating both plasma sampling and direct inner ear fluid analysis to define concentration profiles and retention times.

Organ toxicity assessments extend beyond the inner ear. Preclinical protocols typically include systemic toxicology screens that encompass conventional organs alongside auditory tissues. Although the inner ear is not routinely sampled in standard toxicological panels, targeted otic evaluations via histopathological studies provide crucial data on cochlear hair cell loss and supporting structure integrity (pasdelou2024ototoxicityahigh pages 5-6). Complementary in vitro systems, such as HEI-OC1 cell assays, cochlear explants, and organoids, serve as early indicators of cytotoxic effects; however, these models lack the complexity of in vivo ADME, particularly regarding the dynamic functions of the BLB and systemic clearance (pasdelou2024ototoxicityahigh pages 7-8).

Finally, available human tolerability data in this context are sparse. Although clinical guidelines exist for monitoring patients administered established ototoxic agents, preclinical studies often rely on animal model projections. Promising candidates such as AC102 display enhanced perilymph half-life and improved efficacy in preserving residual hearing after cochlear insults, yet comprehensive human safety profiles and tolerability data remain to be developed in subsequent clinical studies (nieratschker2024anovelpyridoindole pages 1-4, pasdelou2024ototoxicityahigh pages 1-2).

In summary, a comprehensive preclinical safety characterization for these small molecules must integrate detailed inner ear distribution studies, examine BLB permeability under various physiologic conditions, assess systemic exposure contrasted with local retention, and conduct organ toxicity evaluations. The sparse human tolerability data underscore the need for continued translational research to bridge preclinical findings with clinical safety outcomes (pasdelou2024ototoxicityahigh pages 8-10, gheorghe2021nanoparticlesforthe pages 10-11).

References:
1. (pasdelou2024ototoxicityahigh pages 1-2): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

2. (pasdelou2024ototoxicityahigh pages 16-16): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

3. (pasdelou2024ototoxicityahigh pages 10-11): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

4. (pasdelou2024ototoxicityahigh pages 2-3): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

5. (pasdelou2024ototoxicityahigh pages 5-6): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

6. (pasdelou2024ototoxicityahigh pages 7-8): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

7. (pasdelou2024ototoxicityahigh pages 8-10): Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, and Gaëlle Naert. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Frontiers in Molecular Neuroscience, May 2024. URL: https://doi.org/10.3389/fnmol.2024.1379743, doi:10.3389/fnmol.2024.1379743. This article has 6 citations and is from a peer-reviewed journal.

8. (sawamura2021analysisofpharmacokinetics pages 2-4): Seishiro Sawamura, Genki Ogata, Kai Asai, Olga Razvina, Takeru Ota, Qi Zhang, Sasya Madhurantakam, Koei Akiyama, Daisuke Ino, Sho Kanzaki, Takuro Saiki, Yoshifumi Matsumoto, Masato Moriyama, Yasuo Saijo, Arata Horii, Yasuaki Einaga, and Hiroshi Hibino. Analysis of pharmacokinetics in the cochlea of the inner ear. Frontiers in Pharmacology, May 2021. URL: https://doi.org/10.3389/fphar.2021.633505, doi:10.3389/fphar.2021.633505. This article has 5 citations and is from a peer-reviewed journal.

9. (gheorghe2021nanoparticlesforthe pages 10-11): Dan Cristian Gheorghe, Adelina-Gabriela Niculescu, Alexandra Cătălina Bîrcă, and Alexandru Mihai Grumezescu. Nanoparticles for the treatment of inner ear infections. Nanomaterials, 11:1311, May 2021. URL: https://doi.org/10.3390/nano11051311, doi:10.3390/nano11051311. This article has 26 citations and is from a peer-reviewed journal.

10. (nieratschker2024anovelpyridoindole pages 1-4): Michael Nieratschker, Erdem Yildiz, Matthias Gerlitz, Sujoy Bera, Anselm J. Gadenstaetter, Anne-Margarethe Kramer, Monika Kwiatkowska, Pavel Mistrik, Lukas D. Landegger, Susanne Braun, Reimar Schlingensiepen, Clemens Honeder, Christoph Arnoldner, and Hans Rommelspacher. A novel pyridoindole improves the recovery of residual hearing following cochlear implantation after a single preoperative application. BioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.14.580226, doi:10.1101/2024.02.14.580226. This article has 1 citations.
